Trend continuation now, the earnings result are really good, CEO is positive about its AK112 to become the best-in-class drug in its field globally. sq&nsq NSCLC, MSSmCRC are big market, it can compete with Keytruda. Also If NSCLC test coming out in mid-year is positive, it could apply for US FDA and sell globally, not just in China.